Our previous studies designed and synthesized novel thiosemicarbazone anti-cancer drugs that induce NDRG1 expression and potently inhibit primary tumor growth in vivo in a variety of cancers including several PC models (16, 34, 37, 38, 39, 40, 41, 42, 98). This evidence concerns the gene NDRG1 and pachyonychia congenita.